Healthcare >> Analyst Interviews >> March 2, 2026

Argenx Builds Momentum on Strong Execution and Expanding Indications

Phipps, Matt
Matt Phipps, Ph.D., is Group Head of Biotechnology Equity Research at William Blair & Co, LLC. He joined the firm in November 2014, after working as a postdoctoral research fellow at Texas Scottish Rite Hospital for Children. In the 2019 StarMine Analyst Awards from Refinitiv, Dr. Phipps was ranked the No. 1 earnings estimator in biotechnology and No. 3 across all industries. Dr. Phipps earned a Ph.D. in cellular and molecular physiology from the University of Alabama at Birmingham and a B.S. in physics in medicine from the University of Notre Dame. Profile
Word count: 2,561

TWST: Tell us about the current trends and themes that are most impacting the space, the subsectors, you watch?

Dr. Phipps: Sure. My coverage